Cynosure, Inc. Announces Presentation of 16 Abstracts at 33rd ASLMS Annual Conference

WESTFORD, Mass., April 3, 2013 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO) today announced the presentation of 16 scientific abstracts at LASER 2013, the 33^rd Annual Scientific Conference of the American Society for Laser Medicine and Surgery (ASLMS). The clinical research includes four abstracts intended to demonstrate the safety and efficacy of the Company's PicoSure picosecond Alexandrite laser technology for aesthetic indications including the removal of tattoos and the improvement of acne scarring and stretch marks. LASER 2013 takes place April 3-7, 2013 at the Sheraton Boston Hotel/Hynes Convention Center in Boston, Massachusetts.

"The PicoSure data being presented at LASER 2013 underscores the clinical benefits of the technology for patients seeking a safe, effective treatment with minimal downtime," said Michael Davin, Cynosure's Chairman and Chief Executive Officer. "Quite simply, PicoSure produced better results with fewer treatments than current modalities, with high levels of patient and physician satisfaction."

PicoSure is the industry's first picosecond laser cleared for the removal of tattoos and benign pigmented lesions. The device received 510(k) clearance from the U.S. Food and Drug Administration at the end of 2012. Cynosure is currently launching PicoSure in the United States.

Unlike longer pulse energy sources whose principal mechanism of action is photothermal or heat-producing, a picosecond laser delivers photothermal and significant photomechanical or acoustic effects. A picosecond laser's pulse is approximately 100 times shorter than the pulse of established treatment modalities, enabling it to treat a range of aesthetic indications with less collateral tissue heating.

Key ASLMS Abstracts on PicoSure
Kenneth A. Arndt, M.D., Jeffrey S. Dover, M.D. and colleagues at SkinCare Physicians in Chestnut Hill, Mass. led a study that focused on the safety and efficacy of the picosecond Alexandrite 755nm laser for achieving significant pigment clearance in the removal of tattoos. A total of 20 subjects were enrolled in the study. Subjects were allowed up to 10 treatments, and follow-up was conducted from one to three months after the last treatment.

"Within three to five treatments, 16 of the 23 tattoos assessed had greater than 75 percent clearance, while 5 had clearance of 51 to 74 percent," the investigators reported. "Our research demonstrated that the PicoSure is not only a safe and highly effective treatment for tattoos, but also clears 50% more rapidly than nanosecond pulsed Q-switched lasers, for years the gold standard for tattoo removal. What differentiates the picosecond laser is its shorter pulse duration, which allows the device to break down and clear the ink particles more quickly."

A study led by Roy Geronemus, M.D. and colleagues at the Laser & Skin Surgery Center of New York, evaluated the effectiveness of the picosecond Alexandrite 755nm laser, delivering sub-nanosecond pulse durations with an optical attachment in the treatment of stretch marks and scarring. Clinical assessment was performed after the final treatment. The assessment demonstrated a greater than 50% improvement in the texture and appearance of stretch marks and a high level of physician and patient satisfaction with the treatment of acne scars.

Three-Year Data on Cellulaze
In addition to Cynosure's picosecond technology, three-year data was presented on the Company's Cellulaze Cellulite Laser Workstation. Barry DiBernardo, M.D., Medical Director of New Jersey Plastic Surgery, led a multicenter study focused on the long-term evaluation of the treatment of cellulite using the Cellulaze Laser Workstation. A single minimally invasive treatment was administered to 27 females with follow-up photos taken periodically up to three years post treatment. This study demonstrated a high level of both patient and physician satisfaction rates up to three years post treatment.

The following abstracts discussing Cynosure's technology will be presented at LASER 2013:

Cutaneous Laser Surgery

• "Confirmatory Study of Picosecond 755nm Alexandrite Laser," Deanne Mraz Robinson, Nazanin Saedi, Kathleen Petrell, Kenneth A. Arndt, Jeffrey S. Dover, SkinCare Physicians, Chestnut Hill, MA, Thomas Jefferson University, Philadelphia, PA
• "Evaluation of a Picosecond 755nm Alexandrite Laser and Defractive Lens Array for Scarring," Jeremy A. Brauer, Lilia M. Correa, Leonard Bernstein, Elizabeth K. Hale, Julie K. Karen, Lori A. Brightman, Elliot T. Weiss, Robert Anolik, Roy G. Geronemus, Laser & Skin Surgery Center of New York, New York, NY
• "We're Not Stretching the Truth: Treatment of Striae with a Picosecond 755nm Alexandrite Laser and Defractive Lens Array," Jeremy A. Brauer, Lilia M. Correa, Leonard Bernstein, Elizabeth K. Hale, Julie K. Karen, Lori A. Brightman, Elliot T. Weiss, Robert Anolik, Roy G. Geronemus, Laser & Skin Surgery Center of New York, New York, NY
• "Long Term (3 Year) Evaluation for the Treatment of Cellulite A Multicenter Study," Barry DiBernardo, Gordon Sasaki, New Jersey Plastic Surgery, Montclair, NJ, Sasaki Aesthetic and Laser Center, Pasadena, CA
• "2 Year Quantitative Data on Impact of Laser Treatment to Increase Skin Thickness and Elasticity," Barry DiBernardo, Gordon Sasaki, University of Medicine and Dentistry of New Jersey, New Jersey Plastic Surgery, Newark/Montclair, NJ, Loma Linda, CA
• "Quantitative and Qualitative Blinded Evaluation of Outcomes of Single Cellulite Treatment Post Six Months," Bruce Katz, Mount Sinai Medical Center, New York, NY
• "Tattoo Removal Using a New 1064nm and 532nm Laser Having a Continuously Variable Spot Size," Eric Bernstein, University of Pennsylvania, Ardmore, PA
• "Treatment of Facial Erythema in Skin Types I-IV Using Combination Long-Pulse and Q-Switched 1064nm Nd:YAG Lasers," Abnoeal Bakus, Dina Yaghmai, Mary Massa, Jerome Garden, Physicians Laser and Dermatology Institute of Chicago, Northwestern University, Rush University Medical School, Chicago, IL
• "Study and Comparison Between Single and Dual Wavelength Laser (755nm and 1064nm) in Hair Removal in Phototypes I-IV: A Clinical and Pathological Study," Adriana Ribe, Gabriel Buendia-Bordera, Ribe Clinic, Barcelona, Spain, Plataforma Laser Teknon, Barcelona, Spain
• "Combined Pulsed Dye Laser and Nd:YAG Laser for the Treatment of Basal Cell Carcinoma," H. Ray Jalian, Mathew Avram, Kelly Stankiewicz, Joshua Shofner, Zeina Tannous, Massachusetts General Hospital, Boston, MA, Lebanese American University, Beirut, Lebanon

Experimental and Translational Research

• "Impact of Pulse Duration From Nanoseconds to Picoseconds on the Thermal and Mechanical Effects During Laser Interaction," Rafael Sierra, Mirko Mirkov, Cynosure, Inc., Westford, MA

International Experience in Lasers in Dermatology

• "Treatment of Dermatosis Papulosa Nigra with 1064nm Nd:YAG Laser in Patients with Fitzpatrick IV-VI Skin Types with One Year Follow-Up," Ashraf Badawi, Mohamed Tome, Fayza Al Ali, Laser Institute, Cairo University, Cairo, Egypt, Rebat University, Khartoum, Sudan, Rashed Hospital, Dubai, United Arab Emirates
• "Laser-Assisted Liposuction Four Years Follow-Up," Xavier Santos, Claudine Soto, Paz Perez, Hospital Universitario Madrid Monteprincipe, Madrid, Spain

Surgical Applications

• "Evaluation of Unique Side Firing 1440nm Fiberlaser for Jowl Reduction and Selective SMAS Tightening," Richard Gentile, Roger Bassin, Northeast Ohio Medical University, Rootstown, OH, Bassin Center for Facial Plastic Surgery, Orlando, FL
• "Evaluation of the 1064nm Nd:YAG Laser for the Treatment of Cervicofacial Adiposity," John Ferguson, Rebecca Ferguson, The Ferguson Clinic, Honolulu, HI, Dothan, AL

The Cutting Edge: "Laser & Skin"

• "Light Delivery to the Skin Through Ablative Conduits," Emil A. Tanghetti, Center for Dermatology and Laser Surgery, Sacramento, CA

Cynosure's presence at LASER 2013 is further supported by the inclusion of its technology in three scientific posters and two clinical application courses:

Scientific Posters

• "Clinical Evaluation and Quantitative Analysis of Axillary Hyperhidrosis Treated with Unique Targeted Laser Energy Delivery Method with 1 Year Follow Up," David Caplin, Parkcrest Plastic Surgery, St. Louis, MO
• "Long Term (3 Year) Evaluation for the Treatment of Cellulite A Multicenter Study," Barry DiBernardo, Gordon Sasaki, New Jersey Plastic Surgery, Montclair, NJ, Sasaki Aesthetic and Laser Center, Pasadena, CA
• "Treatment of Cellulite in Thighs with a New Laser Technology, Clinical Study," Adriana Ribe, Montserrat Planas, Ribe Clinic, Barcelona, Spain, Policlinic Torreblanca, Sant Cugat del Valle, Spain

Clinical Application Courses

• "Treating Hyperhidrosis," Deanne Robinson, SkinCare Physicians, Chestnut Hill, MA
• "Invasive Treatment of Cellulite," Barry E. DiBernardo, New Jersey Plastic Surgery, Montclair, NJ

About ASLMS
The American Society for Laser Medicine and Surgery, Inc. (ASLMS) is the world's largest scientific organization dedicated to promoting research, education and high standards of clinical care in the field of medical laser applications. It provides a forum for the exchange of scientific information and participates in communicating the latest developments in laser medicine and surgery to clinicians, research investigators, government and regulatory agencies, and the public.

About Cynosure, Inc.
Cynosure develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, remove multi-colored tattoos, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite and treat onychomycosis. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, visit Cynosure's website at www.cynosure.com.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc. and its technology, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, Cynosure's ability to maintain its profitability, competition in the aesthetic laser industry, general business and economic conditions, effects of acquisitions that Cynosure has made or may make, Cynosure's ability to develop and commercialize new products, Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, and economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

Contact:

Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com

SOURCE Cynosure, Inc.